Medical/Pharmaceuticals
Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Ph...
2022-12-15 14:00
2394
IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA
GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) for the company's IND appl...
2022-12-15 13:08
3737
XINGIMAGING and MITRO BIOTECH CO., LTD. to DELIVER FULL-SERVICE CRO OPERATIONS TO CHINA
NEW HAVEN, Conn., Dec. 15, 2022 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd. each highly recognized for drug development and imaging solutions, announce today that they will join forces to provide comprehensive contract research services inChina. The company will be a leading par...
2022-12-15 12:53
2347
Stemirna receives Emergency Use Authorization from Laos for its proprietary mRNA vaccine
SHANGHAI, Dec. 14, 2022 /PRNewswire/ -- On December 8, 2022, Stemirna Therapeutics Co., Ltd. (Stemirna), a Chinese biotech startup specialized inmRNA technology-based drug development, received an Emergency Use Authorization (EUA) from the Food and Drug Department under the Ministry of Health of ...
2022-12-15 12:27
3606
CGTN: How China strengthens vaccine cooperation to battle COVID-19
BEIJING, Dec. 15, 2022 /PRNewswire/ -- Since the outbreak of COVID-19, the world has raced against time, battling the pandemic as it wreaked havoc across the globe. Developing safe and effective vaccines is one of the most crucial steps in the fight against the virus. For the last nearly three y...
2022-12-15 09:16
2433
"Gowajee" - a Thai Speech-Recognition AI from Chula
BANGKOK, Dec. 15, 2022 /PRNewswire/ -- Chula Engineering professors have
designed "Gowajee", a Thai-language speech recognition AI with the accuracy of
a native speaker that keeps users' data secure – now rolled out in call
centers, and being used for depression patients screening.
2022-12-15 09:00
2822
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other m...
2022-12-15 08:00
3151
Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund
SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financing co-led by Eight Roads Ve...
2022-12-15 08:00
2612
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest M...
2022-12-15 08:00
5922
Novavax Announces Proposed $125 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its c...
2022-12-15 05:39
3261
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock...
2022-12-14 23:47
2202
Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs)with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at...
2022-12-14 21:00
1681
BPK9 International Hospital Achieves GHA Accreditation for Medical Travel Services
PALM BEACH GARDENS, Fla., Dec. 14, 2022 /PRNewswire/ -- Global Healthcare
Accreditation (GHA) is pleased to announce that BPK9 International Hospital in
Bangkok, Thailand (https://www.bangpakokhospital.com/en/
2022-12-14 19:00
2297
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...
2022-12-14 15:17
3930
CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients
BEIJING, Dec. 14, 2022 /PRNewswire/ -- To echo China's new guidelines for COVID-19 prevention and control, local governments and hospitals across the country have been optimizing medical services and the allocation of medical resources to face a likely surge in patients and take better care of th...
2022-12-14 12:36
2357
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
2022-12-14 01:41
3658
Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers, today announced a presentation for the Company's CFI-400945 program, a first in class inhibitor of Polo-like Kinase ...
2022-12-13 22:30
3504
VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry
VeriSIM Life eliminates waste and inaccuracy, accelerates preclinical development, and lowers costs and risks when converting drug candidates to clinical trials, and brings life-saving drugs to market faster. SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the artif...
2022-12-13 21:00
1693
HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors
Financings Planned to Support Rapid Expansion of Histotripsy Platform as
Company Welcomes Silk Road Medical CEO,Erica Rogers, to its Board of Directors
MINNEAPOLIS, Dec. 13, 2022 /PRNewswire/ -- HistoSonics, Inc. (
www.histosonics.com
2022-12-13 20:00
2033
CUVET Successfully Developed the First Stem Cell Transplantation Technology to Treat Pet Diabetes
BANGKOK, Dec. 13, 2022 /PRNewswire/ -- For the first time in Thailand, a research team from Chula's Faculty of Veterinary Science (CUVET), led by Assistant Professor Dr. Chenpop Sawangmek in collaboration with Bio ink Co., Ltd., a Chula spinoff company, has successfully developed a method to cultu...
2022-12-13 17:35
2580
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
9065
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
7332
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6976
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6749
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6707
